GALT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases...

Stats
Today's Volume	288 595
Average Volume	176 096
Market Cap	187.57M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.09
ATR14	$0.00700 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Zordani Richard A. Jr.	Buy	1 000	Common Stock
2024-04-24	Lewis Joel	Buy	1 000	Common Stock
2023-12-31	Czirr James C	Buy	0
2024-04-22	Czirr James C	Sell	21 323	Common Stock
2024-04-23	Czirr James C	Sell	3 677	Common Stock

INSIDER POWER
24.03
Last 97 transactions
Buy: 4 249 863 \| Sell: 2 389 317

Volume Correlation

Long: -0.01 (neutral)

Short: -0.97 (very strong negative)

Signal:(42.356) Neutral

Galectin Therapeutics Inc Correlation

10 Most Positive Correlations
SCTL	0.961
MESO	0.953
LABP	0.952
STOK	0.947
BRACU	0.946
KIN	0.945
CDXC	0.939
PFSW	0.938
PESI	0.937
BRY	0.932

10 Most Negative Correlations
DCRC	-0.928
LUCD	-0.927
AHPI	-0.923
IMV	-0.922
NCBS	-0.921
HAIN	-0.921
TENX	-0.92
AEY	-0.92
LAWS	-0.919
CFMS	-0.919

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Galectin Therapeutics Inc Correlation - Currency/Commodity

0.16
( neutral )

-0.37
( neutral )

0.00
( neutral )

0.35
( neutral )

0.23
( neutral )

Galectin Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2023
Revenue:	$0
Gross Profit:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2022
Revenue:	$0
Gross Profit:	$-32 000.00 (0.00 %)
EPS:	$-0.660

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Realtime updates for Galectin Therapeutics Inc [GALT]

Upcoming Earnings Alert